Literature DB >> 17552070

OMERACT/OARSI initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis.

Laure Gossec1, Gillian Hawker, Aileen M Davis, Jean Francis Maillefert, L Stefan Lohmander, Roy Altman, Jolanda Cibere, Philip G Conaghan, Marc C Hochberg, Joanne M Jordan, Jeffrey N Katz, Lyn March, Nizar Mahomed, Karel Pavelka, Ewa M Roos, Maria E Suarez-Almazor, Gustavo Zanoli, Maxime Dougados.   

Abstract

OBJECTIVE: Time to theoretical indication of joint replacement surgery has been proposed as a primary outcome for potential structure-modifying interventions for osteoarthritis (OA). The objectives of this OMERACT/OARSI Working Group were to identify pain, physical function, and structure states that represent the progression from early to late disease for individuals with OA of the hip and knee, and to create a composite measure of these 3 domains to define states of OA severity and a surrogate measure of "need for joint replacement surgery."
METHODS: For pain, focus groups and one-on-one interviews were used. For function, Rasch analysis was performed on existing indices the Hip Dysfunction and Osteoarthritis Outcome Score (HOOS) and the Knee injury and Osteoarthritis Outcome Score (KOOS), each of which subsumes the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) questions. For structure, a comparison of existing indices (Kellgren-Lawrence, OARSI stages, and joint space width) was performed for the hip and the knee.
RESULTS: For pain, key features of pain that are most distressing to people with OA from early to late disease were identified. For function, the reduction of the number of items based on the existing indices continues. For structure, the analysis is also ongoing.
CONCLUSION: Preliminary results were presented at OMERACT 8; the final objective will be to combine the 3 domains (pain, function, and structure) and to create a composite index that could define states of severity and "need for total joint replacement," which could be used to evaluate treatment response to disease-modifying drugs in OA clinical trials.

Entities:  

Mesh:

Year:  2007        PMID: 17552070

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  28 in total

Review 1.  Pharmacologic therapy for osteoarthritis--the era of disease modification.

Authors:  David J Hunter
Journal:  Nat Rev Rheumatol       Date:  2010-11-16       Impact factor: 20.543

2.  Effects of umbilical cord mesenchymal stem cells loaded with graphene oxide granular lubrication on cytokine levels in animal models of knee osteoarthritis.

Authors:  Xiao-Dong Wang; Xiao-Chun Wan; Ai-Feng Liu; Rong Li; Qiang Wei
Journal:  Int Orthop       Date:  2020-06-16       Impact factor: 3.075

Review 3.  OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis.

Authors:  P Ornetti; K Brandt; M-P Hellio-Le Graverand; M Hochberg; D J Hunter; M Kloppenburg; N Lane; J-F Maillefert; S A Mazzuca; T Spector; G Utard-Wlerick; E Vignon; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2009-02-09       Impact factor: 6.576

4.  The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement.

Authors:  L Gossec; S Paternotte; J F Maillefert; C Combescure; P G Conaghan; A M Davis; K-P Gunther; G Hawker; M Hochberg; J N Katz; M Kloppenburg; K Lim; L S Lohmander; N N Mahomed; L March; K Pavelka; L Punzi; E M Roos; L Sanchez-Riera; J A Singh; M E Suarez-Almazor; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2010-10-31       Impact factor: 6.576

5.  A Functional Neuroimaging Study of Expectancy Effects on Pain Response in Patients With Knee Osteoarthritis.

Authors:  Randy L Gollub; Irving Kirsch; Nasim Maleki; Ajay D Wasan; Robert R Edwards; Yiheng Tu; Ted J Kaptchuk; Jian Kong
Journal:  J Pain       Date:  2018-01-08       Impact factor: 5.820

6.  OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group.

Authors:  Laure Gossec; Simon Paternotte; Clifton O Bingham; Daniel O Clegg; Philippe Coste; Philip G Conaghan; Aileen M Davis; Giampaolo Giacovelli; Klaus-Peter Gunther; Gillian Hawker; Marc C Hochberg; Joanne M Jordan; Jeffrey N Katz; Margreet Kloppenburg; Arturo Lanzarotti; Keith Lim; L Stefan Lohmander; Nizar N Mahomed; Jean Francis Maillefert; Rebecca L Manno; Lyn M March; Steven A Mazzuca; Karel Pavelka; Leonardo Punzi; Ewa M Roos; Lucio C Rovati; Helen Shi; Jasvinder A Singh; Maria E Suarez-Almazor; Eleonora Tajana-Messi; Maxime Dougados
Journal:  J Rheumatol       Date:  2011-08       Impact factor: 4.666

Review 7.  Biomarkers for osteoarthritis: current position and steps towards further validation.

Authors:  David J Hunter; Michael Nevitt; Elena Losina; Virginia Kraus
Journal:  Best Pract Res Clin Rheumatol       Date:  2014-02       Impact factor: 4.098

8.  Clinical predictors of elective total joint replacement in persons with end-stage knee osteoarthritis.

Authors:  Joseph A Zeni; Michael J Axe; Lynn Snyder-Mackler
Journal:  BMC Musculoskelet Disord       Date:  2010-05-06       Impact factor: 2.362

9.  Hip pain and mobility deficits--hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association.

Authors:  Michael T Cibulka; Douglas M White; Judith Woehrle; Marcie Harris-Hayes; Keelan Enseki; Timothy L Fagerson; James Slover; Joseph J Godges
Journal:  J Orthop Sports Phys Ther       Date:  2009-04       Impact factor: 4.751

10.  Reliability and clinically important improvement thresholds for osteoarthritis pain and function scales: a multicenter study.

Authors:  Jasvinder A Singh; Ruili Luo; Glenn C Landon; Maria Suarez-Almazor
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.